MADRID — Much of the coverage on Merck at the European Society for Medical Oncology congress centered on its Moderna-partnered cancer vaccine trial. But the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.